Group 1 - Jinhai Medical (920925) experienced a decline of 14.76% today, with a turnover rate of 32.59% and a transaction volume of 517 million yuan, showing a fluctuation of 14.83% [2][3] - The stock was listed on the daily turnover board due to its turnover rate reaching 32.59%, with a net selling amount of 158 million yuan from brokerage seats [3] - The top five brokerage seats accounted for a total transaction volume of 224 million yuan, with a buying amount of 33.13 million yuan and a selling amount of 191 million yuan, resulting in a net selling of 158 million yuan [3] Group 2 - The largest buying brokerage was Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities, with a buying amount of 6.9757 million yuan, while the largest selling brokerage was Guotai Haitong Securities, Chongqing Jiefangbei, with a selling amount of 58.6743 million yuan [3] - Detailed trading information shows that multiple brokerage seats from Dongfang Caifu Securities were involved in buying, with significant amounts also sold by other brokerages [3]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Group 1 - The stock price of Jinhai Medical (920925) closed at 27.84 yuan on January 7, 2026, down 14.76% from the previous trading day, with a total market capitalization of 2.741 billion yuan [1] - The stock opened at 31.44 yuan, reached a high of 31.44 yuan, and a low of 27.38 yuan, with a trading volume of 5.17 billion yuan and a turnover rate of 32.59% [1] - Jinhai Medical announced a 2025 restricted stock incentive plan, granting a total of 200,000 shares to three incentive objects, with senior management Zhang Liang receiving 100,000 shares (50.00%), Yuan Jinpeng receiving 50,000 shares (25.00%), and core employee Zhong Mei receiving 50,000 shares (25.00%) [1]

Core Viewpoint - On January 7, 2026, Jinhao Medical (920925) was featured on the stock exchange's "Dragon and Tiger List" due to a significant trading volume, with a turnover rate of 32.59% and a transaction amount of 517 million yuan [1][2]. Trading Activity Summary - The total trading volume for Jinhao Medical on that day was 18.02 million shares, with a total transaction value of 517 million yuan [1]. - The top buying seat was from Dongfang Caifu Securities, which purchased approximately 6.98 million yuan worth of shares [2]. - The top selling seat was from Guotai Haitong Securities, which sold approximately 58.67 million yuan worth of shares [2]. Detailed Trading Data - The following are the top trading departments: - Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities Office: Buy 6,975,733.27 yuan, Sell 5,376,321.64 yuan [2]. - Bank of China International Securities, Shenzhen Branch: Buy 6,745,707.59 yuan, Sell 34,084 yuan [2]. - Dongfang Caifu Securities, Lhasa East Ring Road Second Securities Office: Buy 6,466,188.67 yuan, Sell 2,651,309.67 yuan [2]. - Guotai Haitong Securities, Chongqing Liberation Monument Office: Buy 0 yuan, Sell 58,674,322.99 yuan [2].

公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、限制性股票激励计划预留权益的分配 1、激励计划获授限制性股票预留权益在各对象间的分配情况如下： | | | | 获授的限 | 占激励计划预留 | 涉及标的股票数量 | | --- | --- | --- | --- | --- | --- | | 序号 | 姓名 | 职务 | 制性股票 | 部分拟授出权益 | 占激励计划公告日 | | | | | 数量（股） | 总量的比例 | 股本总额的比例 | | 1 | 张亮 | 高级管理人员 | 100,000 | 50.00% | 0.10% | | 2 | 袁金鹏 | 高级管理人员 | 50,000 | 25.00% | 0.05% | | 3 | 钟梅 | 核心员工 | 50,000 | 25.00% | 0.05% | | | 合计 | | 200,000 | 100.00% | 0.20% | 证券代码：920925 证券简称：锦好医疗 公告编号：2026-003 注：以上百分比计算结果出现差异是由于四 ...

证券代码：920925 证券简称：锦好医疗 公告编号：2026-002 惠州市锦好医疗科技股份有限公司 第三届董事会第十九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 31 日 2.会议召开地点：公司会议室 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事王敏因公以通讯方式参与表决。 董事王芳因公以通讯方式参与表决。 董事李忠轩因工作原因以通讯方式参与表决。 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2025 年 12 月 26 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 （二）会议出席情况 董事郑能恒因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2025 年限制性股票激励计划预留 ...

广东东方昆仑(东莞)律师事务所 关于 惠州市锦好医疗科技股份有限公司 2025 年第四次临时股东会 之 法律意见书 广东东方昆仑(东莞)律师事务所 KUN LUN DONGGUAN LAW FIRM 二〇二六年一月 广东东方昆仑(东莞)律师事务所 关于 惠州市锦好医疗科技股份有限公司 2025 年第四次临时股东会 之 法律意见书 致:惠州市锦好医疗科技股份有限公司 广东东方昆仑(东莞)律师事务所(下称"本所")接受惠州市锦好医疗科 技股份有限公司(下称"公司")的委托,并根据《中华人民共和国公司法》(下 称"《公司法》"）、《中华人民共和国证券法》(下称"《证券法》")、《上 市公司股东会规则(2025年修订)》(下称"股东会规则")、《上市公司信 息披露管理办法》(下称"信息披露管理办法")等中华人民共和国(下称"中 国",为本法律意见书之目的,不包括香港特别行政区、澳门特别行政区和台湾 地区)的法律、行政法规、规章和规范性文件(下称"法律、法规、规范性文件") 以及现行有效的《惠州市锦好医疗科技股份有限公司章程》(下称"《公司章程》") 的有关规定,指派本所律师李丽丽律师、黄瑞平律师出席公司 2025年第 ...

证券代码：920925 证券简称：锦好医疗 公告编号：2026-001 惠州市锦好医疗科技股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 31 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议与网络投票相结合的方式召开 4.会议召集人：董事会 5.会议主持人：王敏先生 6.召开情况合法合规的说明： 2025 年 12 月 12 日，公司召开第三届董事会第十八次会议审议通过《关于 提请召开 2025 年第四次临时股东会的议案》，并于 2025 年 12 月 15 日在北京证 券交易所信息披露平台（http://www.bse.cn/）刊登了本次股东会的通知公告。本 次股东会的召集、召开、议案审议程序等符合《公司法》、《公司章程》及相关法 律法规的有关规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 5 人，持有表决权的股份总数 59,555,10 ...

Core Viewpoint - JinHao Medical (920925) experienced a significant decline of 14.57% in its stock price, with a trading volume turnover rate of 32.55% and a total transaction value of 597 million yuan, indicating high volatility in the market [2] Trading Activity Summary - The stock was listed on the North Exchange due to its turnover rate reaching 32.55%, with a total net sell of 47.16 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction value of 191 million yuan, with a buying amount of 71.88 million yuan and a selling amount of 119 million yuan, resulting in a net sell of 47.16 million yuan [2] - The largest buying brokerage was Dongfang Securities Co., Ltd. Shanghai Qingpu District Wuxie Bang Road Securities Business Department, with a buying amount of 25.89 million yuan, while the largest selling brokerage was CITIC Securities Co., Ltd. Beijing Branch, with a selling amount of 28.80 million yuan [2] Detailed Brokerage Activity - The top five buying brokerages and their respective amounts were: - 1st: Dongfang Securities, 25.89 million yuan - 2nd: Dongya Qianhai Securities, 16.18 million yuan - 3rd: Dongfang Caifu Securities, 9.22 million yuan - 4th: Dongfang Caifu Securities, 9.14 million yuan - 5th: Huatai Securities, 9.00 million yuan [2] - The top five selling brokerages and their respective amounts were: - 1st: CITIC Securities, 28.80 million yuan - 2nd: CITIC Jiantou Securities, 22.72 million yuan - 3rd: Dongfang Caifu Securities, 22.43 million yuan - 4th: GF Securities, 16.79 million yuan - 5th: Bohai Securities, 16.69 million yuan [2]

Core Viewpoint - On January 6, 2026, Jinhao Medical (920925) was featured on the trading leaderboard of the Beijing Stock Exchange due to a high turnover rate of 32.55%, with a trading volume of 17.9983 million shares and a transaction value of 597 million yuan [1][2]. Group 1 - Jinhao Medical's closing price on the trading day was 32.66 yuan [1]. - The top buying seat was from Dongfang Securities Co., Ltd., Shanghai Qianpu District, with a purchase amount of approximately 25.89 million yuan [1][2]. - The top selling seat was from CITIC Securities Co., Ltd., Beijing Branch, with a selling amount of approximately 28.80 million yuan [1][2]. Group 2 - The total transaction amount for Jinhao Medical on that day reached 597 million yuan [1]. - The trading volume was reported at 17.9983 million shares [1]. - The turnover rate of 32.55% indicates significant trading activity for the stock [1].